Human papillomavirus type 18 E6 and E7 (HPV18 E6/E7)

Human papillomavirus type 18 (HPV18) E6 and E7 are potent viral oncogenes essential for the development and maintenance of HPV-associated malignancies. The E6 protein facilitates the proteasomal degradation of the tumor suppressor p53 through its interaction with the E3 ubiquitin ligase E6AP, thereby inhibiting apoptosis and allowing for the accumulation of DNA damage [2, 4, 10]. Simultaneously, the E7 protein binds and inactivates the retinoblastoma protein (pRb), which releases E2F transcription factors to drive the cell into an uncontrolled S-phase and promote continuous proliferation [4, 9, 14]. These oncoproteins cooperatively disrupt critical host cell cycle checkpoints and induce genomic instability, leading to the malignant transformation of infected epithelial cells [1, 9]. Because E6 and E7 are constitutively expressed in HPV-driven cancer cells and are foreign to the human host, they serve as primary targets for therapeutic interventions, including DNA vaccines, adoptive T-cell therapies, and gene-editing technologies like CRISPR/Cas9 [6, 10, 15]. Persistent expression of these genes is responsible for a significant proportion of cervical, anal, and oropharyngeal cancers worldwide [7, 14, 20].

Other names

HPV18 early proteins 6 and 7Human papillomavirus type 18 early genesHPV18 oncogenesHuman papillomavirus type 18 E6 proteinHuman papillomavirus type 18 E7 proteinHPV18 E6/E7 DNA

Induction of antigen-specific CD8+ T-cell responses; Targeted gene disruption via CRISPR/Cas9 or TALENs; RNA interference (siRNA/antisense) to knockdown viral transcripts; Inhibition of viral transcription by targeting host factors (e.g., CDK9).